News & Videos - BLUEPRINT MEDICINES

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire CAMBRIDGE, Mass., April 18, 2024 CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday , May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428 (domestic)...

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics PR Newswire CAMBRIDGE, Mass., April 11, 2024 ­ -- Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members of Blueprint Medicines' management team to provide a perspective on the mast cell as a promising target for treating allergic and inflammatory disease on April 25, 2024 , at 10:00 a.m. ET -- -- First in...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., April 4, 2024 CAMBRIDGE, Mass. , April 4, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective April 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,711 shares of its common stock and an aggregate of 1,854 restricted stock units (RSUs) to...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., March 6, 2024 CAMBRIDGE, Mass. , March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective March 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,615 shares of its common stock and an aggregate of 1,307 restricted stock units (RSUs) to...

Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire CAMBRIDGE, Mass., Feb. 23, 2024 -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable safety supporting long-term treatment, consistent with real-world experience observed in commercial setting -- -- Preclinical data for BLU-808, a highly selective and potent oral wild-type KIT...

Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results PR Newswire CAMBRIDGE, Mass., Feb. 15, 2024 -- Achieved $204.2 million in AYVAKIT ® /AYVAKYT ® (avapritinib) net product revenues in 2023, including $71.0 million in the fourth quarter -- -- Anticipate global AYVAKIT net product revenue of approximately $360 million to $390 million in 2024, representing >80 percent year-over-year growth at the midpoint -- -- Nine presentations highlighting AYVAKIT long-term safety and...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Feb. 5, 2024 CAMBRIDGE, Mass. , Feb. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective February 1, 2024 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 1,717 shares of its common stock and an aggregate of 858 restricted stock units (RSUs) to...

Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 PR Newswire CAMBRIDGE, Mass., Feb. 1, 2024 CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 15, 2024 , to report its fourth quarter and full year 2023 financial results and provide a corporate update. To access the live conference...

Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SAN FRANCISCO, Jan. 8, 2024 -- AYVAKIT ® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. launch and recent EU approval -- -- Expanding mast cell disease leadership with oral wild-type KIT inhibitor, BLU-808, advancing into clinical development; IND submission planned in Q2 2024 -- --...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Jan. 5, 2024 CAMBRIDGE, Mass. , Jan. 5, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective January 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 9,393 shares of its common stock and an aggregate of 4,696 restricted stock units (RSUs) to...

Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire CAMBRIDGE, Mass., Dec. 18, 2023 CAMBRIDGE, Mass. , Dec. 18, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland , Chief Executive Officer, will present a corporate overview and 2024 outlook at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 , at 10:30 a.m. PT ( 1:30 p.m. ET ). A live webcast of the presentation will be...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis PR Newswire CAMBRIDGE, Mass., Dec. 12, 2023 -- In the European Union, patients with indolent systemic mastocytosis now have an approved medicine that treats the primary driver of disease -- -- Approval based on data from PIONEER trial, in which AYVAKYT achieved significant improvements across a broad range of symptoms with a safety profile...

Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting PR Newswire CAMBRIDGE, Mass., Dec. 9, 2023 -- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership -- CAMBRIDGE, Mass. , Dec. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Dec. 4, 2023 CAMBRIDGE, Mass. , Dec. 4, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective December 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 2,503 shares of its common stock and an aggregate of 1,251 restricted stock units (RSUs) to...

Blueprint Medicines to Present at JMP Securities Hematology and Oncology Summit PR Newswire CAMBRIDGE, Mass., Nov. 28, 2023 CAMBRIDGE, Mass. , Nov. 28, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that company management will participate virtually in a fireside chat at the JMP Securities Hematology and Oncology Summit on Tuesday, December 5, 2023 at 11:00 a.m. ET . A live webcast of the presentation will be available by visiting the Investors & Media...

Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis PR Newswire CAMBRIDGE, Mass., Nov. 10, 2023 -- For the first time, the estimated 40,000 patients with indolent SM in the EU 1,2* would have a medicine that treats the primary disease driver 3,4 -- -- Opinion based on the positive PIONEER trial, in which once-daily AYVAKYT achieved significant improvements across a broad range of symptoms with a comparable...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Nov. 3, 2023 CAMBRIDGE, Mass. , Nov. 3, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective November 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 5,034 shares of its common stock and an aggregate of 2,517 restricted stock units (RSUs) to...

Blueprint Medicines Reports Third Quarter 2023 Results PR Newswire CAMBRIDGE, Mass., Oct. 26, 2023 -- Achieved $54.2 million in AYVAKIT®/AYVAKYT® (avapritinib) net product revenues, representing 90% growth year-over-year, and $56.6 million in total revenues in the third quarter of 2023 – -- Approximately 800 patients on AYVAKIT in the U.S. at the end of the third quarter, more than 35% growth in treated patients quarter-over-quarter and driven by ISM -- -- Plan to present data from Part 1 of...

Blueprint Medicines to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 PR Newswire CAMBRIDGE, Mass., Oct. 12, 2023 CAMBRIDGE, Mass. , Oct. 12, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, October 26, 2023 , to report its third quarter financial results and provide a corporate update. To access the live conference call, please dial 833-470-1428...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass., Oct. 5, 2023 CAMBRIDGE, Mass. , Oct. 5, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective October 1, 2023 , the Compensation Committee of Blueprint Medicines' Board of Directors granted non-qualified stock options to purchase an aggregate of 3,655 shares of its common stock and an aggregate of 1,827 restricted stock units (RSUs) to...